

## **RUNDSCHREIBEN Nr. 87/ ALLGEMEIN/ 2021**

### **VERBOTENE SUBSTANZEN**

Wir weisen auf die mit 1. Jänner 2022 in Kraft tretenden Verbotliste der World-Anti-Doping-Agency (WADA) hin. Entsprechend des von FINA, im Anhang an dieses Rundschreiben übermittelten Memorandums, wollen wir auf die hervorgehobenen Änderungen aufmerksam machen.

Insbesondere ersuchen wir die modifizierten Anwendungsintervalle und Dosierungen des nicht- TUE-pflichtigen Beta- 2 Agonisten Salbutamol zu beachten.

Bitte diese Änderungen an sämtliche Athleten ihres Vereines zu kommunizieren.

Wien, 15.11.2021

**ÖSTERREICHISCHER SCHWIMMVERBAND**

Walter Bär, e.h.  
OSV Sportdirektor

Dear Madam or Sir,

The World Anti-Doping Agency (WADA) has just published the 2022 List of Prohibited Substances and Methods (List); the 2022 Summary of Major Modifications and Explanatory Notes; and the 2022 Monitoring Program. The List comes into force on 1st January 2022.

[https://www.wada-ama.org/sites/default/files/resources/files/2022list\\_final\\_en.pdf](https://www.wada-ama.org/sites/default/files/resources/files/2022list_final_en.pdf)

[https://www.wada-ama.org/sites/default/files/resources/files/2022list\\_explanatory\\_note\\_final\\_en.pdf](https://www.wada-ama.org/sites/default/files/resources/files/2022list_explanatory_note_final_en.pdf)

[https://www.wada-ama.org/sites/default/files/resources/files/2022list\\_monitoring\\_program\\_final\\_en.pdf](https://www.wada-ama.org/sites/default/files/resources/files/2022list_monitoring_program_final_en.pdf)

As outlined in the 2022 Summary of Major Modifications and Explanatory Notes, the Major Modifications for 2022 include the following:

### **1. Glucocorticoids (Class S.9)**

The draft 2021 List, which was considered by WADA's ExCo during its September 2020 meeting, proposed prohibiting all injectable routes of administration of glucocorticoids in-competition. While this modification was approved, the ExCo asked WADA Management to implement the prohibition only as of 1 January 2022, to allow enough time for stakeholders to learn and adapt to this change.

**Therefore, all injectable routes of administration will now be prohibited for glucocorticoids during the in-competition period.**

Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous.

For clarification: oral administration of glucocorticoids, which remains prohibited in-competition, includes, in particular, oromucosal, buccal, gingival and sublingual routes.

Other routes of administration (including inhaled and topical: dental-intracanal, dermal, intranasal, ophthalmological and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

It is strongly recommended that athletes follow the minimum washout periods, expressed from the time of administration to the start of the in-competition period. These washout periods, which are highlighted in the Summary of Major Modifications and Explanatory Note, are based on the use of these medications according to the maximum manufacturer's licensed doses.

If there is a legitimate medical need for the use of a glucocorticoid, the athlete may apply for a Therapeutic Use Exemption (TUE). In case of an AAF in-competition, the athlete may apply for a retroactive TUE as provided for in the applicable rules.

For further information regarding WADA's approach to the routes of administration of glucocorticoids and washout periods, please refer to the Summary of Major Modifications and Explanatory Note.

## **2. Beta-2 Agonists – Dosage of Salbutamol (Class S.3)**

Regarding salbutamol, **the daily dosing time intervals are modified to 600 micrograms over eight hours starting from the time any dose is taken (previously 800 micrograms over 12 hours)**. This is to reduce the risk of any potential AAF arising after high doses are taken at once. The total permitted daily dose remains at 1,600 micrograms over 24 hours. A TUE should be sought for doses in excess of these limits.

For further information on the permitted dosage of salbutamol, please refer to the Summary of Major Modifications and Explanatory Note.

## **3. Non-approved Substances (Class S.0)**

For the first time, a substance has been included by name as an example in section S0 (Non-approved Substances) of the List. This substance, BPC-157, is an experimental peptide sold as a supplement, and it has been included in the 2022 List following a recent re-evaluation of its status.

The 2022 Prohibited List; the 2022 Summary of Modifications and Explanatory Notes; and the 2022 Monitoring Program will be available for download on FINA's website.

<https://www.fina.org/anti-doping/prohibited-list>

We kindly request you to forward this List and all the related Notes to all your athletes and athlete support personnel.

Thank you for your kind cooperation and we remain at your disposal for any question you may have.

Sincerely yours,

Johan Lefebvre  
Medical, Antidoping & Integrity Dpt.